Literature DB >> 8122121

Corticosteroid pulse therapy in active rheumatoid arthritis.

B L Weusten1, J W Jacobs, J W Bijlsma.   

Abstract

The infusion of high doses of corticosteroids (corticosteroid pulse therapy, CPT) is used to treat refractory rheumatoid arthritis (RA). In the first part of this article, literature on the efficacy of CPT is reviewed, and different CPT regimens (high-dose, low-dose, oral CPT) are compared. Several CPT regimens are beneficial in RA, the clinical effect lasting 4 to 10 weeks. Only high-dose CPT (1,000 mg methylprednisolone intravenously) has been shown to bridge the gap between the start and the effect (lag time) of a disease-modifying antirheumatic drug initiated at the same time. A retrospective study on the incidence of short-term and long-term side effects of CPT in 50 patients with RA who received a total of 78 pulse regimens is described in the second part. Side effects occurred frequently, but in most cases they were mild. The possible relationship between CPT and osteonecrosis of the femoral head is discussed. It is concluded that CPT is beneficial in RA. A substantial number of patients suffer side effects of varying severity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8122121     DOI: 10.1016/s0049-0172(05)80039-3

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  20 in total

1.  Chronic asthma.

Authors:  C Cates
Journal:  BMJ       Date:  2001-10-27

Review 2.  [Cortisone therapy today].

Authors:  Hanns Kaiser
Journal:  Wien Klin Wochenschr       Date:  2003-01-31       Impact factor: 1.704

Review 3.  Gastroprotective action of glucocorticoid hormones during NSAID treatment.

Authors:  L P Filaretova; T T Podvigina; T R Bagaeva; A Tanaka; K Takeuchi
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

4.  Indirect role of alpha2-adrenoreceptors in anti-ulcer effect mechanism of nimesulide in rats.

Authors:  Halis Suleyman; Zekai Halici; Elif Cadirci; Ahmet Hacimuftuoglu; Sait Keles; Fatma Gocer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-20       Impact factor: 3.000

5.  The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon gamma and interleukin 4 production.

Authors:  C M Verhoef; J A van Roon; M E Vianen; F P Lafeber; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1999-01       Impact factor: 19.103

6.  Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy.

Authors:  Jiing-Chyuan Luo; Full-Young Chang; Tseng-Shing Chen; Yee-Yung Ng; Han-Chieh Lin; Ching-Liang Lu; Chih-Yen Chen; Hsiao-Yi Lin; Shou-Dong Lee
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 7.  Activation of the hypothalamo-hypophyseal-adrenocortical system as an important gastroprotective component of the stress reaction.

Authors:  L P Filaretova
Journal:  Neurosci Behav Physiol       Date:  2007-05

8.  Head-to-head comparative pharmacokinetic and biodistribution (PK/BD) study of two dexamethasone prodrug nanomedicines on lupus-prone NZB/WF1 mice.

Authors:  Xin Wei; Gang Zhao; Xiaobei Wang; Nagsen Gautam; Zhenshan Jia; Zhifeng Zhao; Dexuan Kong; Fan Zhang; Sushil Kumar; Yuanyuan Sun; Ningrong Chen; Xiaoyan Wang; Libin Yang; Rongguo Ren; Geoffrey M Thiele; Tatiana K Bronich; James R O'Dell; Yazen Alnouti; Dong Wang
Journal:  Nanomedicine       Date:  2020-07-15       Impact factor: 5.307

9.  A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment.

Authors:  P Durez; A Nzeusseu Toukap; B R Lauwerys; D H Manicourt; P Verschueren; R Westhovens; J-P Devogelaer; F A Houssiau
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

10.  Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial.

Authors:  T Pincus; C J Swearingen; G Luta; T Sokka
Journal:  Ann Rheum Dis       Date:  2008-12-15       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.